BILTRICIDE

LOE Approaching

praziquantel

Bayer

NDAORALTABLETPriority Review

Approved

Dec 1982

Lifecycle

LOE Approaching

Competitive Pressure

30/100

Clinical Trials

Mechanism of Action

[see Microbiology ( )] .

Pharmacologic Class:

Anthelmintic

Indications (9)

older for the treatment of the following infections: • Schistosomiasis due to all species of schistosoma (for example Schistosoma mekongi Schistosoma japonicum Schistosoma mansoni Schistosoma hematobium )• Clonorchiasis Opisthorchiasis due to the liver flukes Clonorchis sinensis Opisthorchis viverrini

Clinical Trials (5)

NCT04314037Phase 1Completed

Bioequivalence Study of Coated Cesol Tablet Formulation Versus Biltricide

Started Jun 2020

36 enrolled

Healthy

NCT04115072Phase 2/3Completed

Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study

Started Sep 2019

116 enrolled

Schistosomiasis

NCT03437447Phase 1Completed

Praziquantel Bioequivalence Study

Started Jun 2018

60 enrolled

Healthy

NCT02315352Phase 1Completed

Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets (ODTs) of Praziquantel (PZQ) and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years

Started Apr 2015

48 enrolled

Healthy

NCT02325713Phase 1Completed

Relative Bioavailability Trial of Oral Dispersible Praziquantel Tablets in Healthy Volunteers

Started Jan 2015

32 enrolled

Healthy

Company

External Resources

Full prescribing information

FDA Drugs@FDA

FDA approval history

RxNorm

Drug nomenclature & identifiers